Balaxi Pharma. - Quaterly Results

The Total revenue for the quarter ended December 2025 of  Rs. 245.94 millions grew by 120.42% from Rs. 111.58 millions.The Net proft of the company remain more or less same to Rs. 15.30  millions from Rs. 17.43 millions ,decline by -12.22%.Operating profit for the quarter ended December 2025 decreased to 30.06 millions as compared to 30.14 millions of corresponding quarter ended December 2024.

(Rs. in Million)

	Quarter ended			Year to Date			Year ended
	202512	202412	% Var	202512	202412	% Var	202503	202403	% Var
Sales	245.94	111.58	120.42	606.12	513.39	18.06	609.88	701.96	-13.12
Other Income	16.24	29.17	-44.33	63.00	50.53	24.68	53.73	23.99	123.97
PBIDT	30.06	30.14	-0.27	89.96	81.39	10.53	78.02	76.35	2.19
Interest	7.34	5.66	29.68	19.89	13.69	45.29	20.58	15.41	33.55
PBDT	22.72	24.48	-7.19	70.07	67.70	3.50	57.44	60.94	-5.74
Depreciation	1.53	1.14	34.21	3.89	3.45	12.75	4.56	5.11	-10.76
PBT	21.19	23.34	-9.21	66.18	64.25	3.00	52.88	55.83	-5.28
TAX	5.89	5.91	-0.34	16.31	16.45	-0.85	16.86	19.33	-12.78
Deferred Tax	0.03	-0.19	-115.79	-0.30	-0.57	-47.37	-0.96	-1.05	-8.57
PAT	15.30	17.43	-12.22	49.87	47.80	4.33	36.02	36.50	-1.32
Equity	110.42	110.42	0.00	110.42	110.42	0.00	110.42	108.98	1.32
PBIDTM(%)	12.22	27.01	-54.75	14.84	15.85	-6.38	12.79	10.88	17.62